Germline genetic polymorphisms may influence chemotherapy response and disease outcome in osteosarcoma

Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity

(2010) Lu Fan et al.   Pharmacogenetics and Genomics

Glutathione S-transferase polymorphisms in osteosarcoma patients

(2010) Carolina Salinas-Souza et al.   Pharmacogenetics and Genomics

Inhibition of Notch pathway prevents osteosarcoma growth by cell cycle regulation

(2009) M Tanaka et al.   BRITISH JOURNAL OF CANCER

Advances in individual prediction of methotrexate toxicity: a review

(2009) Kjeld Schmiegelow   BRITISH JOURNAL OF HAEMATOLOGY

MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer

(2009) Ning Sun et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Involvement of gene polymorphisms of the folate pathway enzymes in gene expression and anticancer drug sensitivity using the NCI-60 panel as a model

(2009) Virginie Charasson et al.   EUROPEAN JOURNAL OF CANCER

Pharmacogenetic Analyses of a Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma With Fluorouracil and Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie

(2009) Eray Goekkurt et al.   JOURNAL OF CLINICAL ONCOLOGY

Methotrexate in Pediatric Osteosarcoma: Response and Toxicity in Relation to Genetic Polymorphisms and Dihydrofolate Reductase and Reduced Folate Carrier 1 Expression

(2009) Ana Patiño-García et al.   JOURNAL OF PEDIATRICS

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

(2009) Penelope A. Bradbury et al.   Pharmacogenetics and Genomics

Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

(2009) D Caronia et al.   PHARMACOGENOMICS JOURNAL

Genetic polymorphisms in the carbonyl reductase 3 geneCBR3 and the NAD(P)H:quinone oxidoreductase 1 geneNQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer

(2008) Javier G. Blanco et al.   CANCER

Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms

(2008) Albert Font et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients

(2008) Suman Lal et al.   CANCER SCIENCE

Polymorphisms inABCG2,ABCC3andCNT1genes and their possible impact on chemotherapy outcome of lung cancer patients

(2008) Phillip J. Müller et al.   INTERNATIONAL JOURNAL OF CANCER

Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis

(2008) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Cisplatin nephrotoxicity: Mechanisms and renoprotective strategies

(2008) N. Pabla et al.   KIDNEY INTERNATIONAL

Clinical significance of GSTM1 and GSTT1 polymorphisms in younger patients with acute myeloid leukemia of intermediate-risk cytogenetics

(2008) Ho Sup Lee et al.   LEUKEMIA RESEARCH

MDR1 Single Nucleotide Polymorphism G2677T/A and Haplotype Are Correlated with Response to Docetaxel-Cisplatin Chemotherapy in Patients with Non-Small-Cell Lung Cancer

(2008) Ji-hong Pan et al.   RESPIRATION

DNA variants in the dihydrofolate reductase gene and outcome in childhood ALL

(2007) S. Dulucq et al.   BLOOD

Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism

(2007) Rita Turello et al.   PEDIATRIC BLOOD & CANCER